The effect of atorvastatin and rosuvastatin on endothelial function in diabetics with coronary heart disease
10.3760/cma.j.issn.0254-9026.2009.10.005
- VernacularTitle:瑞苏伐他汀与阿托伐他汀对2型糖尿病并发冠心病患者血管内皮功能的影响
- Author:
Zheng WANG
;
Weimin LI
;
Hongli CHEN
;
Hongyan ZHOU
;
Huiying CHANG
- Publication Type:Journal Article
- Keywords:
Coronary disease;
Diabetes;
type 2;
Antilipemic agents;
Endothelium;
vascular
- From:
Chinese Journal of Geriatrics
2009;28(10):816-819
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the effect of atorvastatin and rosuvastatin on endothelial function in diabetics with coronary heart disease. Methods A total of 73 consecutive diabetics with coronary heart disease who were not receiving statins were randomized to receive atorvastatin 20 mg/d or rosuvastatin 10 mg/d. The levels of lipids, high-sensitivity C-reactive protein(hs-CRP), monoxide nitrogen(NO), endothelin-1 (ET-1) and endothclium-dependent relaxing function(EDF) were assessed before and after 3 months of the treatment. Results The treatment with statins significantly improved endothelial function in diabetics with coronary heart disease. For both rosuvastatin group and atorvastatin group in pro-treatment versus post-treatment, EDF was higher[(5.2±2.4)% vs. (7.9±3.1)%, P=0.008; (5.0±2.8)% vs. (7.6±3.6)%, P=0.024, respectively], NO was also higher((46.6±14.5) μmmol/L vs. (73.3±18.5) μmmol/L; (51.7±14.0) μmmol/L vs. (79.8±16.0) μmmol/L,both P<0.001], ET-1 was lower[(108.2±29.6) pg/L vs. (77.5±26.4) pg/L, P =0.005;(117.1±34.5) pg/L vs. (80.7±28.2) pg/L, P= 0.003, respectively],and hs-CRP was lower[3.17(1.33～6.32) mg/Lvs. 1.39(0.81～2.58) mg/L, P=0.006; 3.43(1.51～7.02) mg/L vs. 1.63(0.69～3.11) mg/L, P = 0.001, respectively]. There were no differences in these between rosuvastatin group and atorvastatin group. Significant negative correlation existed between EDF and hs-CRP. Conclusions A 3 months treatment with either atorvastatin 20 mg/d or rosuvastatin 10 mg/d is effective in improving endothelial function in diabetics with coronary heart disease.
